The significant revenue miss and wider-than-expected net loss are likely to pressure the stock near-term. Monitor upcoming clinical data readouts for MGC028 and MGC026 in H1 2027, as pipeline catalysts are the primary value drivers for this clinical-stage biotech.
Drugs in focus
MGNX drug pipeline →lorigerlimab
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- Unknown — the drug is in Phase 2 with no registrational trial announced. If the lower-dose LINNET data in H1 2027 is compelling enough to support a registrational path, a potential BLA filing would likely be at least 2-3 years away.
- Next catalyst
- None dated
What to watchThe next catalyst is updated LINNET results at a lower 3 mg/kg Q3W dose, expected in H1 2027, positive data could de-risk the safety profile and support registrational discussions, while further safety issues or weak efficacy would likely impair the asset's value. Meanwhile, watch for partnership/licensing interest in lorigerlimab or the broader pipeline (MGC026), and monitor the stock's elevated ~11% short interest (~10.9 days to cover) which could amplify moves on binary events.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $2.20entry
- T+1 · 20h ago −1.36%α +0.55% · $2.17
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MacroGenics reported Q3 2026 revenue of $18.7M, well below the $39.2M consensus, and a GAAP net loss of $20.1M (EPS -$0.32) vs. consensus EPS of -$0.13. The revenue miss was driven by the absence of large milestone payments that boosted the prior-year quarter. The company ended the quarter with $287.7M in cash, extending its runway through 2028, and highlighted pipeline progress with MGC028, MGC026, and lorigerlimab.
Key Financial Metrics
Key Facts
- Total revenue of $18.7M for Q3 2026, down 64.8% from $53.0M in Q3 2025, missing the $39.2M consensus.
- GAAP net loss of $20.1M (EPS -$0.32) vs. net income of $16.8M in Q3 2025; consensus EPS was -$0.13.
- Cash, cash equivalents and marketable securities of $287.7M as of September 30, 2026, up from $189.9M at year-end 2025; cash runway guidance through 2028.
- Received $119.6M from sale of GMP manufacturing operations to Bora, $24.5M regulatory milestone from Sanofi, and $10.0M option license payment from Gilead during Q3.
- Pipeline progress: MGC028 Phase 1 dose escalation completed, MGC026 interim data at ESMO, first patient dosed with MGC030, and lorigerlimab Phase 2 interim results reported.
Financial Impact
Revenue miss of ~$20.5M vs. consensus; net loss of $20.1M vs. consensus loss of ~$8.3M (based on consensus EPS -$0.13 × 63.7M shares).
Risk Factors
- Revenue heavily dependent on milestone payments; core collaboration revenue declined sharply.
- Clinical-stage pipeline with no approved products; regulatory and development risks remain high.
- Stock is volatile (normal daily move 9.6%) and may overreact to the earnings miss.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402151 |
Track record
21 reports on MGNX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Viewing Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers